Browsing by Author "Parkin, Donald Maxwell"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    The burden of Burkitt lymphoma in Africa
    (Infectious agents and cancer, 2019) Hämmerl, Lucia; Colombet, Murielle; Rochford, Rosemary; Ogwang, David Martin; Parkin, Donald Maxwell
    Burkitt lymphoma (BL) is a relatively common cancer of childhood in tropical Africa, although its precise incidence and continent-wide geographic distribution have not been previously systematically studied. Methods: Using the methods employed to produce national estimates of cancer incidence for the “Globocan” series of the International Agency for Research on Cancer, along with detailed information on cancer incidence by histological subtype from cancer registries in Africa, we estimate the numbers and rates of incidence by sex, age group, country and region of Africa. Results: We estimate that the number of new cases that occurred in 2018 to be about 3900, two thirds in males, and 81% in children aged 0–14. On a national basis, the geographic distribution of incidence rates among children in sub-Saharan Africa resembles that of the prevalence of infection with Falciparum malaria. An estimated 81% of cases are associated with infection with Epstein Barr virus (EBV). Conclusions: BL comprises almost 50% of childhood of non-Hodgkin lymphoma in Africa, almost all of which are associated with EBV, with the geographic distribution – at least in sub Saharan Africa - mediated by infection with malaria.
  • Thumbnail Image
    Item
    Survival from childhood cancer in Kampala, Uganda
    (Wiley Subscription Services, Inc, 2021-03) Liu, Biying; Youlden, Danny R; Wabinga, Henry; Nambooze, Sarah; Amulen, Phoebe Mary; Aitken, Joanne F; Parkin, Donald Maxwell
    Abstract Population-based data on survival from childhood cancers in sub-Saharan Africa are sparse.We report data on 221 children with cancer diagnosed between 2010 and 2014 in the population of Kampala, Uganda. Survival for eight of nine children with cancer assessed was below the WHO’s global target of 60% (the exception was Hodgkin lymphoma: 86% at 3 years). There was significant (P < .05) decline in survival between 1 and 3 years for Wilms tumour and Kaposi sarcoma (30% and 34% at 3 years, respectively). Survival from Burkitt lymphoma, Wilms tumour and Kaposi sarcoma has not changed compared with results from the 2005-2009 study